Page 5 note on peer reviews for OA008:
"These results have been written up astwo manuscripts and submitted toleading journals for peer review. The firstmanuscript details the outcomes of thePARA_OA_008 Phase 2 trial and thesecond manuscript compares thePARA_OA_008 results to currentlyavailable and pipeline therapies forosteoarthritis. Peer-reviewed publicationsplay a critical role in establishing scientificcredibility, enhancing visibility within themedical community, and providingvalidation of the clinical data underpinning our program"
- Forums
- ASX - By Stock
- PAR
- Ann: Appendix 4D and Half Year Report
PAR
paradigm biopharmaceuticals limited..
Add to My Watchlist
3.23%
!
30.0¢

Ann: Appendix 4D and Half Year Report, page-2
Featured News
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
|
|||||
Last
30.0¢ |
Change
-0.010(3.23%) |
Mkt cap ! $114.8M |
Open | High | Low | Value | Volume |
31.0¢ | 31.0¢ | 29.0¢ | $83.40K | 273.4K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
2 | 52746 | 30.0¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
31.0¢ | 86658 | 6 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 50000 | 0.300 |
2 | 44274 | 0.295 |
5 | 41076 | 0.290 |
8 | 113434 | 0.285 |
20 | 365670 | 0.280 |
Price($) | Vol. | No. |
---|---|---|
0.310 | 68879 | 5 |
0.315 | 59233 | 3 |
0.320 | 108906 | 8 |
0.325 | 174028 | 8 |
0.330 | 2746 | 1 |
Last trade - 14.09pm 18/06/2025 (20 minute delay) ? |
Featured News
PAR (ASX) Chart |
The Watchlist
MEM
MEMPHASYS LIMITED.
Professor John Aitken, Scientific Director
Professor John Aitken
Scientific Director
Previous Video
Next Video
SPONSORED BY The Market Online